Highlights,Hemogenyx Pharmaceuticals secures funding for phase I trials of its HEMO-CAR-T therapy.,The therapy focuses on ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on KURA stock, giving a Buy rating today. Salim Syed’s rating ...

About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and ...

HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update. Hemogenyx Pharmaceuticals has secured a £600,000 investment from an institutional ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

AML: Acute myeloid leukemia; CLL: C-type lectin-like molecule; CXCR: CXC chemokine receptor; N/A: Not applicable; NF: Nuclear factor. Acute myeloid leukemia (AML) remains incurable for the ...

The daughter of “FDR Democrats” in New Jersey, she’d worked first as a clinical psychologist. But, after a few years, she found herself drawn to the field of law, “for its political relevance and ...

Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present a variety of abstracts that aim to improve treatments for patients with lymphoma and acute leukemias at ...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the ...

Cellectis has deprioritized one of its leukemia-focused candidates in order to focus on its other two clinical-stage CAR-T therapies. | Cellectis has deprioritized one of its leukemia-focused ...

In a recent publication of the acute myeloid leukemia (AML) arm of the Tumor Profiler, researchers demonstrated that multi-OMICS profiles can be generated in a clinically meaningful turnaround time ...